These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 8378092

  • 1. Activation of gene transcription by the amino terminus of the N-Myc protein does not require association with the protein encoded by the retinoblastoma suppressor gene RB1.
    Cziepluch C, Wenzel A, Schürmann J, Schwab M.
    Oncogene; 1993 Oct; 8(10):2833-8. PubMed ID: 8378092
    [Abstract] [Full Text] [Related]

  • 2. The retinoblastoma susceptibility gene product regulates Myc-mediated transcription.
    Adnane J, Robbins PD.
    Oncogene; 1995 Jan 19; 10(2):381-7. PubMed ID: 7838535
    [Abstract] [Full Text] [Related]

  • 3. v-Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation.
    Min S, Taparowsky EJ.
    Oncogene; 1992 Aug 19; 7(8):1531-40. PubMed ID: 1630816
    [Abstract] [Full Text] [Related]

  • 4. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.
    Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H.
    Nature; 1992 Oct 01; 359(6394):423-6. PubMed ID: 1406955
    [Abstract] [Full Text] [Related]

  • 5. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
    Crouch DH, Fisher F, Clark W, Jayaraman PS, Goding CR, Gillespie DA.
    Oncogene; 1993 Jul 01; 8(7):1849-55. PubMed ID: 8510929
    [Abstract] [Full Text] [Related]

  • 6. c-Myc does not require max for transcriptional activity in PC-12 cells.
    Ribon V, Leff T, Saltiel AR.
    Mol Cell Neurosci; 1994 Jun 01; 5(3):277-82. PubMed ID: 8087425
    [Abstract] [Full Text] [Related]

  • 7. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc.
    Austen M, Cerni C, Lüscher-Firzlaff JM, Lüscher B.
    Oncogene; 1998 Jul 30; 17(4):511-20. PubMed ID: 9696045
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Functional analysis of the N-terminal domain of the Myc oncoprotein.
    Oster SK, Mao DY, Kennedy J, Penn LZ.
    Oncogene; 2003 Apr 03; 22(13):1998-2010. PubMed ID: 12673205
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K, Anand G, Yin X, Grove L, Prochownik EV.
    Oncogene; 1998 Mar 05; 16(9):1149-59. PubMed ID: 9528857
    [Abstract] [Full Text] [Related]

  • 12. Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding.
    McEwan IJ, Dahlman-Wright K, Ford J, Wright AP.
    Biochemistry; 1996 Jul 23; 35(29):9584-93. PubMed ID: 8755740
    [Abstract] [Full Text] [Related]

  • 13. Opposite transcriptional activity between the wild type c-myc gene coding for c-Myc1 and c-Myc2 proteins and c-Myc1 and c-Myc2 separately.
    Batsché E, Crémisi C.
    Oncogene; 1999 Oct 07; 18(41):5662-71. PubMed ID: 10523846
    [Abstract] [Full Text] [Related]

  • 14. Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product.
    Rustgi AK, Dyson N, Bernards R.
    Nature; 1991 Aug 08; 352(6335):541-4. PubMed ID: 1865909
    [Abstract] [Full Text] [Related]

  • 15. Transcriptional activation domain of the muscle-specific gene-regulatory protein myf5.
    Braun T, Winter B, Bober E, Arnold HH.
    Nature; 1990 Aug 16; 346(6285):663-5. PubMed ID: 2385294
    [Abstract] [Full Text] [Related]

  • 16. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X, Giap C, Lazo JS, Prochownik EV.
    Oncogene; 2003 Sep 18; 22(40):6151-9. PubMed ID: 13679853
    [Abstract] [Full Text] [Related]

  • 17. DNA binding by N- and L-Myc proteins.
    Ma A, Moroy T, Collum R, Weintraub H, Alt FW, Blackwell TK.
    Oncogene; 1993 Apr 18; 8(4):1093-8. PubMed ID: 8455937
    [Abstract] [Full Text] [Related]

  • 18. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
    Rao G, Alland L, Guida P, Schreiber-Agus N, Chen K, Chin L, Rochelle JM, Seldin MF, Skoultchi AI, DePinho RA.
    Oncogene; 1996 Mar 07; 12(5):1165-72. PubMed ID: 8649810
    [Abstract] [Full Text] [Related]

  • 19. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
    Epinat JC, Kazandjian D, Harkness DD, Petros S, Dave J, White DW, Gilmore TD.
    Oncogene; 2000 Feb 03; 19(5):599-607. PubMed ID: 10698504
    [Abstract] [Full Text] [Related]

  • 20. Transcriptional activation by human c-myb and v-myb genes.
    Kalkbrenner F, Guehmann S, Moelling K.
    Oncogene; 1990 May 03; 5(5):657-61. PubMed ID: 2189102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.